A framework for assessing the value of laboratory diagnostics;Un cadre pour évaluer la valeur des diagnostics en laboratoire

Healthcare Management Forum

Volumn 25, Issue SUPPL. 3, 2012, Pages S4-

  Anonychuk, Andrea ^a   Beastall, Graham ^b   Shorter, Simon ^a   Kloss Wolf, Regina ^a   Neumann, Peter ^c  

^a ABBOTT DIAGNOSTICS   (United States)

^b International Federation of Clinical Chemistry and Laboratory Medicine   (United Kingdom)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867950243     PISSN: 08404704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hcmf.2012.07.015     Document Type: Article

References (48)

1. MaRS Discovery District Life sciences: molecular diagnostics New tools for evidence-based medicine 2009 MaRS Discovery District Toronto, Ontario, Canada
2. D. Drummond Public services for Ontarians: a path to sustainability and excellence 2012 Commission on the Reform of Ontario's Public Services Ottawa, Ontario, Canada
3. T. Closson Achieving a high performing health care system Ontario Hospital Association, Breakfast with the Chiefs 2012 Ontario Hospital Association Toronto, Ontario, Canada
4. The Lewin Group, Inc Laboratory medicine: a national status report 2008 The Lewin Group, Inc. Falls Church, VA
5. P.R. Billings Three barriers to innovative diagnostics Nat Biotechnol 24 2006 917 918 (Pubitemid 44215380)
6. M.J. Hallworth The; 1970% claim': what is the evidence base? Ann Clin Biochem 48 2011 487 488
7. The Lewin Group, Inc The value of diagnostics innovation, adoption and diffusion into health care 2005 The Lewin Group, Inc. Falls Church, VA
8. J.G. Lijmer, M. Leeflang, P.M. Bossuyt Proposals for a phased evaluation of medical tests Med Decis Making 29 2009 E13 E21
9. T.A. Trikalinos, U. Siebert, J. Lau Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations Med Decis Making 29 2009 E22 E29
10. S.J. Lord, L. Irwig, P.M. Bossuyt Using the principles of randomized controlled trial design to guide test evaluation Med Decis Making 29 2009 E1 E12
11. D.W. Lee, P.J. Neumann, J.A. Rizzo Understanding the medical and nonmedical value of diagnostic testing Value Health 13 2 2010 310 314
12. C. Fang, H.J. Otero, D. Greenberg Cost-utility analyses of diagnostic laboratory tests: a systematic review Value Health 14 8 2011 1010 1018
13. M.R. Langlois, P. Wallemacq The future of hospital laboratories Position statement from the Royal Belgian Society of Clinical Chemistry (RBSCC) Clin Chem Lab Med 47 10 2009 1195 1201
14. P.M. Bossuyt, K. McCaffery Additional patient outcomes and pathways in evaluations of testing Med Decis Making 29 2009 E30 E38
15. P.J. Neumann, J.T. Cohen, J.K. Hammitt Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents Health Econ 21 2012 238 251
16. C.P. Price Point of care testing BMJ 322 2001 1285 1288
17. Medicines and Healthcare Products Regulatory Agency http://www.mhra.gov. uk Accessed June 06, 2012
18. T.M. Bailey, T.M. Topham, S. Wantz Laboratory process improvement through point-of-care testing Jt Comm J Qual Improv 23 7 1997 362 380
19. E. Lee-Lewandrowski, K. Lewandrowski Perspectives on cost and outcomes for point-of-care testing Clin Lab Med 29 2009 479 489
20. G.G. Rao, M. Crook, M.L. Tillyer Pathology tests: is the time for demand management ripe at last? J Clin Pathol 56 2003 243 248 (Pubitemid 36459791)
21. W.S. Smellie Appropriateness of test use in pathology: a new era or reinventing the wheel? Ann Clin Biochem 40 2003 585 592 (Pubitemid 37421704)
22. Home of the best practice in primary care pathology project web site BetterTesting.org.uk http://www.bettertesting.org.uk/ Accessed June 06, 2012
23. R.E. Thomas, B.L. Croal, C. Ramsay Effect of enhanced feedback and brief educational reminder messages on laboratory test requesting in primary care: a cluster randomised trial Lancet 367 2006 1990 1996 (Pubitemid 43867700)
24. H. Ross, J. Howlett, J.M. Arnold Treating the right patient at the right time: access to heart failure care Can J Cardiol 22 9 2006 749 754 (Pubitemid 44227471)
25. Public Health Agency of Canada Tracking heart disease and stroke in Canada 2009 Public Health Agency of Canada Ottawa
26. Heart and Stroke Foundation of Canada The growing burden of heart disease and stroke 2003 Heart and Stroke Foundation of Canada Ottawa, ON
27. US Centers for Disease Control and Prevention Heart disease and stroke prevention, addressing the nation's leading killers: at a glance 2011 http://www.cdc.gov/ Accessed June 6, 2012
28. L. Liao, L.A. Allen, D.J. Whellan Economic burden of heart failure in the elderly Pharmacoeconomics 26 6 2008 447 662
29. N. Lopez-Andrès, P. Rossignol, W. Iraqi Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (cardiac resynchronization in heart failure) trial Eur J Heart Fail 14 1 2012 74 81
30. Ho JE, Liu C, Lyass A, et al. Gal-3. Predicts incident heart failure in the community. Paper presented at: American College of Cardiology's 61st Annual Scientific Session & Expo, March 26 2012; Chicago, IL,.
31. R.A. de Boer, D.J. Lok, T. Jaarsma Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
32. C.R. deFilippi, M. Michael Felker Galectin-3 in heart failure: linking fibrosis, remodelling and progression European Cardiology 6 2 2010 33 36
33. Anand I.Galectin-3 in relation to prognosis and effect of valsartan treatment - results of Val-HeFT trial. Paper presented at: American College of Cardiology 61st Annual Scientific Session & Expo. March 26 2012; Chicago, IL.
34. Stein K.Galectin-3 in candidates for CRT treatment: a MADIT-CRT substudy. Paper presented at: American College of Cardiology 61st Annual Scientific Session & Expo. March 26 2012; Chicago, IL.
35. C.C. Welles, I.A. Ku, D.M. Kwan Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study J Am Coll Cardiol 59 7 2012 673 680
36. A. Boutwell, S. Hwu Effective interventions to reduce rehospitalizations: a survey of the published evidence 2009 Institute for Healthcare Improvement Cambridge, MA
37. R. Kornowski, D. Zeeli, M. Averbuch Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure Am Heart J 129 1995 762 766
38. G. Nichol, P. Kaul, E. Huszti Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure Ann Intern Med 141 2004 343 351
39. American Heart Association Lifestyle changes for heart failure http://www.heart.org Accessed June 6, 2012
40. S. Faubel, L.S. Chawla, G.M. Chertow Ongoing clinical trials in AKI Clin J Am Soc Nephrol 7 2012 861 873
41. J.A. Kellum, R. Bellomo, C. Ronco Definition and classification of acute kidney injury Nephron Clin Pract 109 2008 c182 c187
42. A.D. Shaw, D.B. Chalfin, J. Kleintjens The economic impact and cost-effectiveness of urinary neutrophil gelatinase-associated lipocalin after cardiac surgery Clin Ther 33 11 2011 1713 1725
43. P. Devarajan Emerging urinary biomarkers in the diagnosis of acute kidney injury Expert Opin Med Diagn 2 2008 387 398 (Pubitemid 351659225)
44. M. Haase, P. Devarajan, A. Haase-Fielitz The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies J Am Coll Cardiol 57 17 2011 1752 1761
45. P.S. McLeod Humana and Norton Healthcare's pilot ACO triggered both increased utilization of clinical laboratory tests and improved patient outcomes http://www.darkdaily.com Accessed July 23, 2012
46. K.A. Schulman, A.V. Vidal, D.C. Ackerly Personalized medicine and disruptive innovation: implications for technology assessment Genet Med 11 8 2009 577 581
47. MaRS Discovery District Excellence in clinical innovation and technology evaluation (EXCITE) http://excite.marsdd.com/ Accessed June 6, 2012
48. The International Society for PharmacoEconomic and Outcomes Research (ISPOR) http://www.ispor.org Accessed July 20, 2012